When multiple myeloma relapses
Patients with relapsed multiple myeloma live longer on Kyprolis®* than on bortezomib*1
Kd superior overall survival
Kyprolis®* demonstrated superiority in efficacy by extending the median overall survival by 7.6 months vs bortezomib thereby reducing the risk of death by 21%.*1
The overall survival difference was consistent regardless of prior bortezomib therapy or number of prior therapies.1
Please read the SmPC for full comprehensive safety information
- Dimopoulos MA, et al. Abstract presented at the 16th International Myeloma Workshop; March 1–4, 2017; New Delhi, India.
- PR Newswire. Amgen presents overall survival data from KYPROLIS® (carfilzomib) phase 3 ENDEAVOR trial at 16th International Myeloma Workshop, available at: http://www.prnewswire.com/news-releases/amgen-presents-overall-survival-data-from-kyprolis-carfilzomib-phase-3-endeavor-trial-at-16th-international-myeloma-workshop-300417521.html, last accessed March 2017.